As dermatology moves toward greater precision in both diagnostics and therapeutics, ultrasound offers a powerful yet underutilized means of enhancing care across aesthetic and medical settings. While adoption in dermatology has historically been limited—largely due to low awareness, training gaps, and limited confidence in image interpretation—recent advances in handheld, high-frequency devices have dramatically improved accessibility and ease of use. These innovations create new opportunities for dermatologists to incorporate ultrasound into everyday practice, from enhancing aesthetic procedural safety through real-time visualization of facial anatomy to detecting hallmark features of hidradenitis suppurativa (HS), including early inflammatory changes, deep collections, and evolving sinus tracts that may not be evident on physical examination. By strengthening clinicians’ proficiency in dermatologic ultrasound and pairing it with up-to-date knowledge of emerging HS therapies, the proposed activity aims to reduce diagnostic delay, improve disease characterization, and support more precise, proactive intervention.

After participating in this activity, learners should be able to:
• Assess the core principles, capabilities, and clinical applications of handheld ultrasound devices to enhance precision in cosmetic procedures and HS assessment
• Examine available and emerging treatment options for individuals with HS
• Interpret real-time ultrasound findings involving HS lesions and facial anatomy mapping
• Apply practical ultrasound techniques in the identification of key cosmetic and HS-related structures to inform appropriate treatment strategies or next steps

Supported by an educational grant from Incyte Corporation.

Talk Title: A Treatment Option for Appropriate Patients With Certain Skin Diseases Driven in Part by Type 2 Inflammation

Speaker: Brad P. Glick, DO, MPH, FAAD, FAOCD
AAD Board of Directors
Program Director, Dermatology Residency
Larkin Health System
Assistant Clinical Professor of Dermatology
Herbert Wertheim College of Medicine
Miami, Florida

Artificial intelligence is rapidly becoming an integral tool in dermatology, offering enhanced diagnostic accuracy, more efficient workflows, and broader access to care. In 2026, practitioners are witnessing AI’s expanding role—from advanced imaging and lesion classification to predictive analytics and virtual triage—while grappling with key challenges such as algorithm bias, regulatory oversight, and data privacy. This session will offer a balanced update on AI’s clinical capabilities, current limitations, and practical considerations for responsibly integrating these tools into daily dermatologic practice.

From AI enhanced diagnostic tools and secure clinical imaging solutions to evolving teledermatology workflows, this session will deliver a dynamic overview of emerging technologies shaping modern dermatologic practice. Attendees will explore not only the latest technical capabilities—such as smartphone-integrated imaging systems, machine learning applications for lesion assessment, and encrypted photo management platforms—but also practical considerations, including privacy compliance and implementation in everyday workflows. The overall goal is to equip clinicians with the knowledge to judiciously adopt tech innovations that will enhance accuracy, efficiency, and patient safety in dermatologic care.

Photoprotection remains a cornerstone of dermatologic prevention and disease management, yet the landscape of sunscreen filters is rapidly evolving. This session will provide an up-to-date overview of newly available and emerging ultraviolet (UV) filters, including advances in organic and inorganic formulations, improved photostability, and enhanced cosmetic elegance. Attendees will explore how modern filters address long-standing challenges such as broad-spectrum coverage, skin sensitivity, environmental impact, and patient adherence. The discussion will also highlight regulatory considerations, differences between U.S. and international sunscreen approvals, and practical guidance for counseling patients amid growing consumer confusion. By integrating the latest science with real-world clinical application, this session aims to equip dermatologists with the knowledge needed to confidently recommend effective, safe, and patient-appropriate sun protection strategies.

Many systemic and dermatologic conditions manifest eye-related symptoms that can offer early warning signs—making basic ophthalmologic awareness invaluable for dermatologists. This session will review essential ocular anatomy, common ocular presentations linked to skin and systemic pathology, and practical assessment techniques suitable for real-world clinical settings. Attendees will learn when initial evaluation and timely referral are warranted, empowering them to incorporate eye care insights into more comprehensive patient management.

Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition that disproportionately affects sebaceous gland-rich areas and poses treatment challenges for many patients. Advances in understanding its underlying immune and microbiome mechanisms are driving the development of newer, more convenient topical options alongside optimized use of traditional therapies. This session will offer practical guidance on individualizing treatment regimens—spanning antifungals, anti-inflammatory agents, and procedural tools—in a way that balances efficacy, safety, and patient adherence.

Mastocytosis is a rare, heterogenous neoplasm characterized by the accumulation of clonal mast cells (MCs) in various tissues. It is classified into cutaneous mastocytosis (CM), systemic mastocytosis (SM), and, rarely, mast cell sarcoma (MCS). SM can present with cutaneous symptoms that may be mistaken for other dermatologic conditions, leading to diagnostic delays. As dermatologists are often the first point of contact for patients with SM, they must be equipped to recognize both cutaneous and systemic features, apply diagnostic tools, and refer patients for systemic evaluation. In recent years, targeted therapies such as avapritinib have emerged, expanding treatment options for both advanced and indolent disease, with ongoing clinical trials investigating several additional tyrosine kinase inhibitors (TKIs). In light of the evolving therapeutic landscape, dermatology clinicians must stay up to date on emerging data and treatment guidelines to improve outcomes for patients with SM. Timely diagnosis and effective management require collaboration among dermatology, hematology, allergy/immunology, and internal medicine. Education is needed among dermatologists on optimal diagnostic approaches, treatment selection strategies, and multidisciplinary management of SM.
After participating in this activity, learners should be able to: • Evaluate current guidelines to identify both cutaneous and systemic features of SM and facilitate timely diagnosis and referral for systemic evaluation
• Assess the mechanism of action, efficacy, and safety data of newer and emerging targeted therapies for SM
• Apply multidisciplinary management strategies for patients with SM to ensure coordinated, comprehensive, and person-centered care

Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Vulvar dermatoses are often misdiagnosed or overlooked, making clinical acumen and patient-centered strategies especially vital. This session will offer practical pearls for effective history-taking and examination—emphasizing techniques like differentiating itch versus pain, conducting a systematic exam with patient comfort, and using oriented biopsy methods. Attendees will learn how to enhance diagnostic accuracy, improve communication, and optimize treatment adherence, with the goal of equipping dermatologists with actionable, empathetic tools to elevate care in the often underrecognized field of vulvar dermatology.

Many systemic diseases with cutaneous manifestations also present with characteristic ocular findings, providing dermatologists with an additional lens for early recognition. This session will examine how conditions such as lupus, dermatomyositis, sarcoidosis, and other autoimmune or inflammatory dermatoses reveal themselves through ocular changes, including dryness, conjunctival inflammation, uveitis, or retinal abnormalities. Attendees will learn practical strategies for identifying these signs during dermatologic evaluation, appreciating their implications for systemic disease management, and understanding when referral to ophthalmology is warranted.

Serologic evaluation plays a pivotal role in diagnosing and monitoring autoimmune diseases in dermatology, but tests must be ordered judiciously to inform care without causing confusion or unnecessary intervention. This session will outline the dermatologist’s framework for selecting and interpreting autoimmune serologies, emphasizing clinical context, pre-test probability, and collaboration with rheumatology colleagues. Attendees will learn to distinguish between supportive versus diagnostic value, manage uncertainty, and align testing strategies with evolving guideline-driven algorithms.

The connection between inflammatory bowel disease (IBD) and dermatologic conditions is increasingly recognized, with skin findings often reflecting underlying intestinal inflammation or therapy-related effects. This session will highlight the spectrum of cutaneous manifestations that may accompany IBD, and the importance of timely recognition and management. Attendees will gain practical strategies for identifying dermatologic signs that may signal gastrointestinal disease, as well as approaches for effective collaboration with gastroenterology specialists.

Talk title: Psoriasis and Obesity: Shared Immunologic Pathways and Clinical Implications

Speakers:

-Ganary Dabiri, MD, PhD Diplomate, American Board of Dermatology; Diplomate, American Board of Obesity Medicine

Andrew Blauvelt, MD, MBA

Talk title: Sailing Into Clear Horizons: Exploring Superiority Data From 5 Head-to-Head Clinical Trials
Speaker: Benjamin Lockshin, MD

Prescribing in pregnancy requires a careful balance between managing maternal conditions and ensuring fetal safety. This session will focus on evidence-informed approaches to evaluating and prescribing dermatologic therapeutics during pregnancy and lactation, emphasizing comprehensive medication review, pharmacokinetic changes in pregnancy, and shared decision-making with patients. Attendees will explore strategies to assess risk, prioritize safer topical options when possible, and thoughtfully integrate systemic therapies when necessary.

Prescription drug costs remain a major challenge, shaped by a complex mix of development expenses, market exclusivity, supply chain dynamics, and the growing use of advanced therapies. These pressures continue to strain healthcare budgets and patient access, while policymakers explore strategies to curb rising expenditures. This session will provide an overview of the key factors driving costs, highlight the evolving policy landscape, and consider the implications for clinicians, healthcare systems, and the dermatology patients they serve.

Identifying high risk pregnancies is essential to ensuring timely, specialized care and optimizing outcomes for both patient and fetus. This session will outline key clinical criteria—such as pre existing conditions, pregnancy-related complications, advanced maternal age, multiple gestation, and fetal concerns—that may warrant consultation with a maternal fetal medicine (MFM) specialist. Attendees can expect guidance on risk assessment strategies, referral timing, and effective coordination with MFM teams to facilitate personalized care planning.

The healthcare reimbursement environment continues to evolve as payers adjust policies in response to economic pressures and shifting models of care. This session will provide an overview of anticipated changes in payment structures, highlighting how these developments may affect practice operations, provider revenue, and patient access. Attendees will gain practical strategies for adapting to these adjustments, including approaches to documentation, compliance, and integration of value-based care principles.

Chronic lichen planus and related lichenoid dermatoses often pose therapeutic challenges, especially in persistent or treatment-resistant cases. This session will explore both foundational approaches—such as topical and systemic corticosteroids, phototherapy, and immune-modulating agents—and emerging, pathogenesis-driven treatments like JAK inhibitors, PDE 4 inhibitors, and biologics targeting IL 17/IL 23 pathways. Attendees will gain insight into when to escalate care, how to individualize treatment based on disease subtype or severity, and where novel therapies are showing promise in clinical practice.

Psoriatic disease is a chronic, immune-mediated condition that includes both psoriasis (PsO) and psoriatic arthritis (PsA). PsO is a prevalent chronic inflammatory disease that affects more than eight million people in the United States, with systemic inflammation that extends well beyond the skin to drive a range of comorbidities including PsA, axial spondyloarthritis (AxPsA), cardiovascular disease (CVD), metabolic-associated fatty liver disease (MAFLD), obesity, and mental health disorders. These comorbidities significantly worsen physical and psychosocial functioning, increase morbidity and mortality, and complicate treatment selection. Growing evidence indicates that systemic therapies—such as tumor necrosis factor (TNF) and interleukin inhibitors (ILs), and newer metabolic agents like glucagon-like peptide-1 (GLP-1) receptor agonists—can address psoriatic inflammation and its metabolic and cardiovascular sequelae, offering a unified approach to treatment. However, fragmented care coordination and limited patient education continue to hinder optimal outcomes. To close these gaps, dermatologists and allied healthcare professionals (HCPs) must be equipped with current evidence on systemic therapies, comorbidity screening, and interdisciplinary collaboration. A comprehensive, patient-centered, and multidisciplinary approach that addresses inflammation, comorbid risk, and adherence behaviors is essential to improving long-term outcomes and quality of life (QoL) for patients living with PsO, PsA, and comorbidities.
After participating in this activity, learners should be able to: • Evaluate the PsO treatment landscape, with a focus on clinical data and mechanisms of biologic agents that also exhibit positive effects on common comorbid conditions • Assess recent updates in the PsA treatment landscape, focusing on the safety/efficacy data of biologic therapies and their impact on relevant comorbidities • Implement strategies to identify and mitigate cardiovascular complications in patients with psoriatic disease • Outline the role of GLP-1R agonists in the management of obesity in patients with psoriatic disease
Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Talk title: A Join Approach to Psoriatic Disease Management: Bimzelx for Your Patients with PSO & PSA
Speakers:
Graham Litchman, DO, MS
Evan Siegel, MD

Cutaneous lupus erythematosus (CLE) can be a trigger or indicator of systemic lupus erythematosus (SLE), requiring dermatologists to stay updated on both its evolving diagnostic nuances and treatment innovations. This session will present key updates on the CLE therapeutic pipeline, highlighting emerging systemic agents and reviewing the most recent guidelines. The discussion will also include the role of dermatologists in multidisciplinary care, and how to integrate shared decision-making to optimize the long-term management of lupus.

Dermatologists frequently encounter manifestations of allergic diseases that overlap with skin presentations, necessitating a solid foundation in allergy fundamentals. This session will guide clinicians through recognizing key signs of allergic involvement—from contact reactions to urticaria and atopic inflammation—while also clarifying when to manage in-house and when specialty referral is warranted. Attendees will gain an understanding of the dermatologist’s role in diagnosis and initial intervention, as well as frameworks for effective collaboration with allergists to optimize patient outcomes.

Systemic sclerosis (SSc) remains a high mortality connective tissue disease with limited disease modifying therapies and significant clinical heterogeneity. This session will spotlight advances in targeted and regenerative treatments—ranging from precision based immunomodulatory agents that disrupt inflammatory and fibrotic pathways to stem cell-based strategies aimed at restoring tissue integrity. Attendees will explore how evolving molecular insights and early clinical innovations are ushering in a shift from reactive management toward proactive, personalized approaches in SSc care.

Psoriatic arthritis is a frequently underdiagnosed comorbidity in patients with psoriasis, yet timely recognition and intervention are critical to preserving function and quality of life. Dermatologists are uniquely positioned to identify early signs and symptoms, integrate screening into routine practice, and collaborate across specialties to ensure comprehensive care. This session will provide practical strategies to help clinicians confidently recognize psoriatic arthritis, initiate appropriate management, and improve outcomes through proactive, patient-centered approaches.

Talk title: ZORYVE® (roflumilast): Discover a New Option in Topical Treatment
Speaker: Brad P. Glick, DO, MPH
Title: Dermatologist and Principal Investigator
Affiliation: GSI Clinical Research

Following Mohs micrographic surgery—especially in sensitive or complex locations—reconstructive collaboration becomes essential to restore anatomy and function while preserving aesthetics. This session will highlight the critical role of plastic surgeons in planning and executing reconstructive options that complement Mohs techniques, such as flap design, grafting, and wound healing approaches. Discussion topics will include multidisciplinary decision-making principles, technical considerations for reconstruction, and strategies to optimize both patient-centered and oncologic outcomes.

The understanding of immune-mediated hair loss is advancing quickly, with new insights into disease mechanisms opening the door to innovative treatment strategies. Emerging therapies are moving beyond traditional approaches, offering the potential for more targeted, personalized care in conditions that have historically been difficult to manage. This session will highlight evolving trends in both diagnostics and treatment, providing dermatologists with practical knowledge to better address complex hair loss disorders.

As inflammatory bowel disease (IBD) management evolves, combination therapy—using multiple agents targeting distinct immune pathways—is emerging as a way to overcome treatment resistance and better control complex disease patterns. Dermatologists can draw inspiration from this model to address challenging cases in dermatologic inflammatory conditions. This session will guide clinicians in thoughtfully applying multi-modal treatment principles, focusing on patient selection, balancing efficacy with safety, and coordinating cross-specialty care.

Contact dermatitis remains a common and clinically significant concern in dermatology, driven by evolving exposure patterns and a diverse range of allergens and irritants. This session will delve into updated approaches for accurate diagnosis—including thoughtful clinical assessment and refined patch-testing strategies—and effective management that balances avoidance, topical therapies, and patient education. Attendees will learn how to recognize emerging allergens and patterns of sensitization, apply tailored diagnostic tools, and deliver care that is both thorough and practical.

Talk title: Adjuvant Treatment with LIBTAYO for Patients with Cutaneous Squamous Cell Carcinoma (CSCC) at High Risk of Recurrence After Surgery and Radiation

Speaker: Daniel Siegel, MD Dermatologist, Mohs Surgeon SUNY Downstate Department of Dermatology Brooklyn, NY

Talk title: Now Approved: A new path forward with RHAPSIDO® (remibrutinib)
Speaker: Dr. Todd Schlesinger

Recent developments in vitiligo treatment are offering fresh hope for patients and clinicians alike by expanding beyond traditional approaches like phototherapy and corticosteroids. Emerging strategies—including advanced topical formulations, immune-targeted therapies, and novel regenerative approaches—are showing promising results in stimulating repigmentation with enhanced safety and personalization. This session will explore the evolving therapeutic landscape while addressing the emotional and psychosocial burdens of vitiligo, enabling dermatologists to offer more comprehensive, patient-centered care.

Advances in biologics, small molecules, and immunotherapies are steadily reshaping the therapeutic landscape of psoriasis (PsO), atopic dermatitis (AD), and hidradenitis suppurativa (HS)—bringing remission into clearer view. This session will explore the translational journey from bench to bedside, highlighting how cytokine-targeted agents, innovative modalities, and microbiome-focused approaches are extending disease control and potentially achieving durable remission. Through a discussion of emerging therapies, mechanistic insights, and clinical trial trajectories, attendees will gain a forward-looking perspective on whether remission across these complex inflammatory skin disorders will become a practical reality in 2026.

Integrating aesthetic-enhancing products into the management of medical skin conditions offers new opportunities to support both health and confidence. This session will examine how carefully selected cosmetic formulations—including cleansers, moisturizers, sunscreens, and non-comedogenic products—can safely complement medical treatments to improve outcomes and patient wellbeing. Attendees will learn practical strategies for advising patients on choosing and incorporating cosmetics that support skin barrier function, reduce irritation, and bolster adherence to therapeutic regimens.

Hyperpigmentation—stemming from factors like sun exposure, inflammation, or skin injury—is among the most common concerns seen in dermatology, particularly pronounced in patients with richly pigmented skin. Effective management requires a thoughtful, layered strategy that may include diligent photoprotection, considerate use of topical lightening agents, and careful selection of in-office procedures when needed. This session will present a balanced approach, weighing efficacy and safety while emphasizing prevention, evidence-informed use of topical and procedural tools, and personalized guidance to optimize outcomes.

Psoriasis (PsO) is a chronic, immune-mediated disease affecting over 7.5 million adults in the United States (US) and more than 100 million people globally, with a high burden of comorbidities such as cardiovascular disease, diabetes, and inflammatory bowel disease. Despite the availability of systemic therapies, a significant proportion of patients with moderate-to-severe PsO remain undertreated or untreated, often due to dissatisfaction with treatment and poor adherence driven by factors like side effects, inconvenience, and lack of alignment with patient preferences. Targeted therapies that address key inflammatory factors and pathways, such as interleukin (IL) 23, IL-17, tumor necrosis factor (TNF)-α, phosphodiesterase (PDE)4, and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, particularly tyrosine kinase 2 (TYK2), offer promising efficacy with potentially improved tolerability. Novel oral small molecule therapies have also recently emerged as attractive options for patients who prefer non-injectable treatments, especially given their convenience and ease of use. As newer targeted oral agents are introduced, it is essential for dermatologists and allied clinicians to understand their mechanisms, efficacy, safety, and optimal place in therapy in order to effectively tailor treatment plans. Education is needed to enhance clinicians' ability to match therapeutic choices with disease characteristics, comorbidities, and individual patient goals to optimize outcomes in moderate-to-severe PsO.
After participating in this activity, learners should be able to: • Assess current unmet needs in managing moderate-to-severe PsO, including the implications of under-treatment, nonadherence, comorbid conditions, and the need for more effective and tolerable therapies • Describe the pathophysiology of PsO, with a focus on the role of the JAK/STAT signaling pathway and the relevance of targeting JAKs and TYK2 for disease management • Evaluate the clinical evidence supporting current and emerging oral therapies for moderate-to-severe PsO, including head-to-head comparisons and long-term efficacy and safety data • Identify appropriate candidates for oral therapies and create individualized treatment strategies that reflect patient preferences, therapeutic efficacy, and safety considerations
Supported by an educational grant from Bristol-Myers Squibb.

Talk title: Bridging Care Across Skin & Joints: An Option to Choose TREMFYA® First
Speaker: Dr. Wallace Nozile
Double board certified dermatologist and micrographic dermatologic surgeon

Despite growing awareness, outcome-measure frameworks in dermatology frequently overlook the nuanced needs of patients with diverse skin tones and other underrepresented groups, risking biased assessments and inequitable treatment decisions. Emphasizing inclusive research methodologies and consensus-driven tools, this panel aims to broaden the relevance and accuracy of dermatologic outcome measures. Attendees will gain an understanding of strategies to integrate a wide range of skin types and perspectives into the development of patient-centered outcome instruments, ensuring validity across populations.

Biologics and small-molecule inhibitors have transformed treatment options for many inflammatory dermatologic conditions—but they also raise important questions about appropriate screening and monitoring. This session will offer evidence-informed guidance on when to conduct baseline tests and how to tailor ongoing surveillance based on agent-specific risk profiles and patient comorbidities. Attendees will learn about real-world practice patterns, variability in monitoring, and practical strategies to optimize both safety and resource use.

Hair and scalp concerns—especially those linked to styling practices and unique dermatologic conditions—are among the most frequent yet under-addressed issues in patients with richly pigmented skin. This session will explore how high-tension hairstyles, hair product use, and cultural hair care routines intersect with conditions like scarring alopecia and seborrheic dermatitis, often contributing to inflammatory scalp changes. Clinicians will be guided through culturally competent diagnostic steps, from history-taking that respects hairstyling practices to biopsy when needed, and learn evidence-informed strategies that combine dermatologic safety with patient preferences.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting up to 2% of adults in the United States (US), characterized by painful nodules, abscesses, and scarring in intertriginous areas such as the axillae and groin. With an average diagnostic delay of up to a decade, many patients experience years of misdiagnosis, ineffective treatments, and significant psychosocial distress. Improved outcomes rely on early recognition, accurate staging, and evidence-based therapy, including the use of FDA-approved biologics—adalimumab, secukinumab, and bimekizumab—that target TNF-α, IL-17A, and IL-17F pathways. Emerging data also highlight the promise of several investigational agents, which may offer an additional targeted approach to controlling the complex inflammatory pathways underlying HS. Multidisciplinary, coordinated care addressing comorbidities, mental health, and reproductive needs is also essential to improving the long-term journey of patients living with HS.

After participating in this activity, learners should be able to: • Recognize the clinical presentations, comorbidities, and consequences of delayed diagnosis in HS to promote timely identification and effective care • Evaluate current data on available and emerging treatment options for HS, including their efficacy, safety profiles, and potential role in individualized, patient-centered care • Apply holistic, multidisciplinary care strategies in the management of HS to optimize patients’ long-term health, function, and quality of life

Supported by an educational grant from UCB.

Dermatomyositis (DM) is a debilitating autoimmune disease whose full clinical and quality-of-life (QoL) burden is often underrecognized, leading to missed opportunities for timely intervention. Early diagnosis remains challenging, as clinicians may struggle to identify subtle or atypical cutaneous signs and to reliably differentiate DM from other inflammatory or autoimmune conditions with overlapping features. These diagnostic uncertainties are compounded by variable use of validated assessment tools and result in delays that can adversely affect long-term outcomes. Although conventional immunosuppressive therapies remain the mainstay of treatment, many patients experience incomplete responses, relapses, or treatment-limiting toxicity, highlighting the need for more effective and targeted options. Emerging data on novel agents—including therapies directed at the Janus kinase/Signal transducer and activator of transcription (JAK/STAT) and tyrosine kinase 2 (TYK2) pathways—demonstrate clinically meaningful promise and represent an important evolution in the DM treatment landscape. Continuing medical education (CME) is therefore critical to enhance clinician understanding of disease burden, strengthen diagnostic proficiency, and prepare providers to interpret and implement new therapeutic strategies as they become available.
After participating in this activity, learners should be able to: • Apply evidence-based strategies for timely DM detection, accurate diagnostic evaluation, and consistent use of validated assessment tools • Evaluate the evolving DM treatment landscape, including emerging targeted therapies with promising mechanisms of action and the potential to improve patient outcomes • Implement interdisciplinary strategies to manage DM and address patient needs
Supported by an educational grant from Priovant Therapeutics.

Talk title: Explore EBGLYSS®(lebrikizumab-lbkz): See How EBGLYSS Can Leave a Lasting Impression
Speaker: Firas Hougeir, MD, FAAD, FASMS, FEADV

Psoriasis (PsO) affects nearly 8 million people in the United States (US) and continues to present major challenges in care. While interleukin-23 (IL-23) inhibitors have transformed care by offering durable responses, many patients struggle with injectable therapies or avoid advanced treatment altogether. The emergence of novel oral agents, including the first investigational oral peptide targeting the IL-23 receptor, offers the potential for biologic-level efficacy with the convenience of a pill. Within this evolving landscape, dermatology clinicians play a pivotal role in evaluating the mechanisms, safety, and efficacy of novel agents, determining their optimal use, and personalizing care to align with patient needs. Education is urgently needed to help clinicians interpret evolving trial data related to emerging oral IL-23 therapies, understand their role relative to injectables, and integrate patient-centered strategies that improve adherence, satisfaction, and long-term disease outcomes.
Learning Objectives: Describe current challenges in PsO care, including undertreatment, treatment nonadherence, and patient dissatisfaction with available options Evaluate the mechanisms of action, efficacy, and safety data of oral IL-23 therapies and other targeted oral agents in PsO Compare oral IL-23 therapy with injectable IL-23 inhibitors and oral small molecules, including head-to-head data Incorporate patient-centered approaches into individualized PsO management strategies Applications for commercial support from healthcare-related industries are pending. Commercial support will be acknowledged as it is received.

Psoriatic arthritis (PsA) is a chronic, heterogeneous inflammatory disease that affects up to 30% of patients with psoriasis (PsO). Dermatologists are uniquely positioned to identify and initiate early management due to the convergence between PsA and PsO. Despite their critical role, however, many dermatologists lack formal training in recognizing and managing PsA, resulting in diagnostic delays, missed opportunities for timely referral to rheumatologists, undertreatment, and suboptimal patient outcomes. Recent advances in understanding of PsA pathogenesis, especially in the areas of cytokine signaling and the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, have led to the emergence of oral treatment options that align with patient preferences and offer effective disease control across multiple domains. These include a Federal Drug Administration (FDA)-approved phosphodiesterase 4 (PDE4) inhibitor and JAK inhibitors, along with promising tyrosine kinase 2 (TYK2) inhibitors currently in late-stage clinical development. However, the rapidly evolving therapeutic landscape challenges clinicians to stay current with mechanisms of action (MOA), safety data, and treatment indications for these oral therapies. Targeted continuing education (CE) is essential to equip dermatology clinicians and allied specialty healthcare providers (HCPs) with the knowledge and confidence needed to improve PsA diagnosis, integrate novel therapies into treatment plans, and deliver personalized, coordinated, and evidence-based care that improves both clinical and quality of life (QoL) outcomes for patients with PsA.
After participating in this activity, learners should be able to: • Summarize unmet needs in PsA care, including delayed diagnosis and undertreatment • Describe the pathophysiology of PsA and the therapeutic implications of targeting the JAK/STAT signaling pathway for PsA treatment • Evaluate the safety, efficacy, and indications of available and emerging oral treatments for PsA • Generate individualized treatment strategies for PsA that consider eligibility for oral treatment, comorbidities, and patient preferences
Supported by an educational grant from Bristol-Myers Squibb.

Cutaneous T cell lymphoma (CTCL) presents as a rare yet complex group of T cell malignancies that frequently challenge conventional treatment approaches. This session will guide clinicians through the evolving landscape of CTCL management—highlighting the role of skin-directed therapies alongside novel systemic and immunologic agents, including recently approved immunotherapies and promising investigational treatments. Emphasis will be placed on multidisciplinary, personalized strategies that balance efficacy, safety, and patient-centered care, while anticipating future therapeutic innovations.

Immune checkpoint inhibitors are transforming oncology—but their high rate of cutaneous immune-related adverse events (cirAEs) poses both diagnostic and management challenges for clinicians. This session will explore the diverse spectrum of skin toxicities—from common maculopapular rashes and lichenoid eruptions to rare but serious reactions like Stevens–Johnson syndrome—that can be associated with cancer immunotherapy. Attendees will also be provided with practical guidelines for early recognition, grading, and treatment to ensure continuation of life-saving therapies whenever possible.

Epidermal growth factor receptor (EGFR) inhibitors are cornerstone treatments in oncology, but they are also frequently accompanied by challenging dermatologic side effects—including acneiform eruptions, xerosis, pruritus, paronychia, and hair changes—that impair quality of life and may disrupt cancer therapy. This session will discuss proactive strategies—such as early patient education, gentle skincare regimens, sun protection, and prophylactic tetracyclines—to reduce severity and preserve adherence to cancer treatments. Attendees will also receive guidance on collaboration with oncology teams for seamless care delivery.